OTHER THERAPIES ON THE HORIZON

Researchers are currently developing a new approach to allergies, using medication that is currently used for asthma patients. This is the administration of a humanized monoclonal anti-IgE antibody omalizumab (Xolair). This product seems to give patients with allergic rhinitis relief. However, it is very expensive at this time and is indicated only for severe asthma. Side
effects include injection-site reaction, viral infections, upper-respiratory infections, sinusitis, headaches, and sore throat. Although rare, anaphylaxis can occur.